Wave Life Sciences WVE Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Ionis PharmaceuticalsIONS

-$20.82M-51.8%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

See full

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

See full

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

See full

Market cap$1.14B+9.2%

Enterprise value$615.92M-27.2%

P/S15.1×-12.2×

Profitability

See full

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

See full

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Wave Life Sciences's increase (decrease) in contract liabilities and current deferred income?: Wave Life Sciences (WVE) reported increase (decrease) in contract liabilities and current deferred income of -$28.25M in Q1 2026.
How has Wave Life Sciences's increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Wave Life Sciences's increase (decrease) in contract liabilities and current deferred income decreased by 207.9% year-over-year, from -$9.18M to -$28.25M.